Aspergillosis - A Pipeline Analysis Report

Overview of the drug development for aspergillosis

Aspergillosis is an infection caused by Aspergillus, a common mold that lives indoors and outdoors. People with a weakened immune system or those with lung diseases are at high risk of developing health problems due to Aspergillus. One kind of the disease is allergic bronchopulmonary aspergillosis also called ABPA, a condition where the fungus causes allergic respiratory symptoms like asthma, wheezing, and coughing, but it does not actually invade and destroy tissues. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with a weakened immune system due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. According to CDC, milder allergic forms of aspergillosis are more common than the invasive form of the infection. As per a study, about 2.5% of adults having asthma also have ABPA, which is approximately 4.8 million people worldwide. Of these 4.8 million people, an estimated 40,000 also have chronic pulmonary aspergillosis. Consequently, with rising incidences of the disease, the drug development for aspergillosis is expected to increase considerably in the recent years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for aspergillosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of aspergillosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Amplyx
• Asahi Kasei
• Biosergen
• Cidara Therapeutics
• Lypro Biosciences

Therapeutic assessment of the drug development for aspergillosis by route of administration

• Oral
• Oral/intravenous
• Inhalation
• Intravenous

The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for aspergillosis by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development for aspergillosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for aspergillosis?
• What are the companies that are currently involved in the development of drug molecules for aspergillosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.